VolitionRx Reports High Accuracy in Feline Cancer Blood Test Study, Advancing Liquid Biopsy for Cats

VolitionRx Limited (NYSE American: VNRX) has announced the submission for peer review of a clinical manuscript demonstrating the high accuracy of its Nu.Q Vet Feline prototype assay in detecting lymphoma in cats. The study, which achieved 97% specificity and identified 86% of cases, represents a significant step forward in the development of a blood-based liquid biopsy test for feline cancer.

The company stated that the technology addresses a substantial unmet need in veterinary medicine, where non-invasive diagnostic tools for cancer are limited. Lymphoma is one of the most common cancers in cats, and early detection is critical for improving treatment outcomes. The Nu.Q Vet test, which measures nucleosomics in the blood, offers a simple, cost-effective alternative to traditional diagnostic methods such as biopsies or imaging.

According to the press release, the publication of this study in a peer-reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment, highlighting the commercial potential of the technology. VolitionRx is working toward product commercialization and expanding its presence in the growing companion animal oncology market, which presents a significant revenue opportunity.

“This milestone underscores our commitment to advancing the science of epigenetics for both human and animal health,” said a company representative. “The high specificity and sensitivity of our prototype test demonstrate its potential to become a valuable tool for veterinarians in diagnosing feline lymphoma.”

VolitionRx is a multi-national company focused on developing simple, easy-to-use, cost-effective blood tests to detect and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. The company’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.

The full press release is available at https://ibn.fm/ARsEY. For more information about VolitionRx and its technology, visit the company’s website at www.Volition.com.

The implications of this study are significant for both veterinary medicine and the company’s financial outlook. If the test receives regulatory approval and commercial adoption, it could transform how feline lymphoma is diagnosed, leading to earlier intervention and better outcomes for cats. Additionally, the milestone payment would provide a substantial boost to VolitionRx’s revenue as it continues to develop its pipeline of liquid biopsy tests.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is VolitionRx Reports High Accuracy in Feline Cancer Blood Test Study, Advancing Liquid Biopsy for Cats.

The post VolitionRx Reports High Accuracy in Feline Cancer Blood Test Study, Advancing Liquid Biopsy for Cats appeared first on citybuzz.